Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Propylthiouracil vs no intervention Early mortality (mortality up to 90 days) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Serious adverse events (proportion) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Serious adverse events (number) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Health‐related quality of life · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline vs no intervention Serious adverse events (number) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Erythrocytapheresis vs phlebotomy Health‐related quality of life beyond one year · people with hereditary haemochromatosis Interventions for hereditary haemochromatosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ciclosporin vs no intervention Serious adverse events (proportion) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ciclosporin vs no intervention Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ciclosporin vs no intervention Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
D‐Penicillamine vs no intervention Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
D‐Penicillamine vs no intervention Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate plus ursodeoxycholic acid (UDCA) vs UDCA Serious adverse events (proportion) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate plus ursodeoxycholic acid (UDCA) vs UDCA Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate plus ursodeoxycholic acid (UDCA) vs UDCA Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ursodeoxycholic acid (UDCA) vs no intervention Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ursodeoxycholic acid (UDCA) vs no intervention Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Azathioprine vs no intervention Serious adverse events (proportion) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Azathioprine vs no intervention Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Azathioprine vs no intervention Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy vs no chemotherapy Short‐term and medium‐term mortality · people with intermediate‐stage hepatocellular carcinoma Management of people with intermediate‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy vs no chemotherapy Adverse events · people with intermediate‐stage hepatocellular carcinoma Management of people with intermediate‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy vs no chemotherapy Quality of life · people with intermediate‐stage hepatocellular carcinoma Management of people with intermediate‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy vs no chemotherapy Disease recurrence · people with intermediate‐stage hepatocellular carcinoma Management of people with intermediate‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Chemotherapy vs no chemotherapy Length of hospital stay · people with intermediate‐stage hepatocellular carcinoma Management of people with intermediate‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Percutaneous alcohol injection vs radiofrequency ablation Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery Management of people with early‐ or very early‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Laser ablation vs radiofrequency ablation Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery Management of people with early‐ or very early‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Laser ablation vs radiofrequency ablation Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery Management of people with early‐ or very early‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Transarterial embolisation plus radiofrequency ablation vs radiofrequency ablation Cancer‐related mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery Management of people with early‐ or very early‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Transarterial embolisation plus radiofrequency ablation vs radiofrequency ablation Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery Management of people with early‐ or very early‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Transarterial embolisation plus percutaneous alcohol injection vs percutaneous alcohol injection Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery Management of people with early‐ or very early‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Transarterial embolisation plus percutaneous alcohol injection vs percutaneous alcohol injection Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery Management of people with early‐ or very early‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Surgery vs radiofrequency ablation Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma eligible for surgery Management of people with early‐ or very early‐stage hepatocellular carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Emotional distress · women with breast cancer Online support groups for women with breast cancer (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Uncertainty · women with breast cancer Online support groups for women with breast cancer (2017) · Cochrane | no estimate extracted | NR | No studies |
Chlorpromazine vs metiapine Mental state: clinically important improvement · people with schizophrenia Chlorpromazine versus metiapine for schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
Chlorpromazine vs metiapine Service use: readmission due to relapse · people with schizophrenia Chlorpromazine versus metiapine for schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
Chlorpromazine vs metiapine Satisfaction of participant or care provider with treatment · people with schizophrenia Chlorpromazine versus metiapine for schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
Chlorpromazine vs metiapine Behaviour: aggressive or violent behaviour · people with schizophrenia Chlorpromazine versus metiapine for schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
Chlorpromazine vs metiapine Cost of care · people with schizophrenia Chlorpromazine versus metiapine for schizophrenia (2017) · Cochrane | no estimate extracted | NR | No studies |
Interferon‐α alone vs interferon‐α plus bevacizumab Quality of life · previously untreated patient with mRCC Immunotherapy for metastatic renal cell carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Interferon‐α plus bevacizumab vs standard targeted therapies Quality of life · previously untreated patients with mRCC Immunotherapy for metastatic renal cell carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Vaccine treatment vs standard therapies Quality of life · previously untreated patients with mRCC Immunotherapy for metastatic renal cell carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Interferon‐α combined with targeted therapies vs standard targeted therapy Quality of life · previously untreated patients with mRCC Immunotherapy for metastatic renal cell carcinoma (2017) · Cochrane | no estimate extracted | NR | No studies |
Back School vs medical care Work status Not reported · people with low back pain Back Schools for chronic non‐specific low back pain (2017) · Cochrane | no estimate extracted | NR | No studies |
Back School vs passive physiotherapy Work status Not reported · people with low back pain. Back Schools for chronic non‐specific low back pain (2017) · Cochrane | no estimate extracted | NR | No studies |
Back School vs exercise Work status Not reported · people with low back pain Back Schools for chronic non‐specific low back pain (2017) · Cochrane | no estimate extracted | NR | No studies |